Trevi Therapeutics Inc () Stock Market info Recommendations: Buy or sell Trevi Therapeutics stock? Trevi Therapeutics stock analysis based on the TipRanks smart score of 8 unique data sets and technical analysis. View real-time stock prices and stock quotes for a full financial overview. Trevi Therapeutics to Present at Stifel Healthcare Conference. Trevi is developing Haduvio ™ (nalbuphine ER) in a range of indications for which patients have few treatment options. TREVI THERAPEUTICS, INC. : News, information and stories for TREVI THERAPEUTICS, INC. | Nasdaq: TRVI | Nasdaq These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. An archived replay of the webcast will also be available for 30 days on the Company’s website following the event. Since then, TRVI shares have decreased by 12.3% and is now trading at $2.79. The transfer agent and registrar for the common stock of Trevi Therapeutics, Inc. stock is Computershare Trust Company, N.A. - Biotechnology Portfolio, FTIF SICAV - Biotechnology Discovery Fund. The average price target is $11.00, with a high forecast of $13.00 and a low forecast of $9.00. Trevi Therapeutics, Inc. Common Stock, also called Trevi Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. Company profile page for Trevi Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information The high price target for TRVI is … Dividend). Trevi is currently conducting a Phase 2b/3 clinical trial of Haduvio, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.About HADUVIO Haduvio is an oral extended release formulation of nalbuphine. A live audio webcast will be accessible from the ‘Investors & News’ section on the Company’s website at www.trevitherapeutics.com. TRVI | Complete Trevi Therapeutics Inc. stock news by MarketWatch. Trevi Therapeutics (TRVI) stock price, charts, trades & the US's most popular discussion forums. 76.4% of retail CFD accounts lose money, * Average Estimates in Million (e.g. A company profile for Trevi Therapeutics, Inc, including a description, key executives, stock price history and more. Check out our TRVI stock analysis, current TRVI quote, charts, and historical prices for Trevi Therapeutics Inc stock The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Commerce Policy | TRVI Stock Fundamentals Get the hottest stocks to trade every day before the market opens 100% free. Shareholder percentage totals can add to more than 100% because some holders are included in the free float. account day-to-day movements in market value compared to a company’s liability structure. Trevi Therapeutics has a one year low of $1.33 and a one year high of $8.50. Trevi Therapeutics to Present at Stifel Healthcare Conference 11/10/2020 NEW HAVEN, Conn. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management The firm has a 50 day simple moving average of $3.17 and a two-hundred day simple moving average of $4.24. During the third quarter of 2020, the Company received $14.0 million in proceeds from a term loan with Silicon Valley Bank and sold approximately $2.5 million of common stock under the Company’s ATM program. TRVI Trevi Therapeutics Inc Quarterly Report (10-q) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Trevi intends to propose Haduvio as the trade name for the nalbuphine ER investigational product. Find the stock by name or ticker symbol: TRVI. Based on Trevi Therapeutics, Inc. (TRVI), the company’s capital structure generated 0.65 points for debt to equity in total, while total debt to capital is set at the value of 0.65. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Search for Trevi Therapeutics. Updated daily, it takes into Stock quotes by finanzen.net, Plus500. We are focused on completing enrollment in both trials and preparing for the next steps in the development of Haduvio.”Key Business Updates * Phase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with prurigo nodularis: The Company has enrolled approximately 190 subjects in the trial and reaffirms its guidance that it expects to complete enrollment in the third quarter of 2021 and to report top-line data in the fourth quarter of 2021. About TRVI Trevi Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Additionally, the Company is assessing additional study sites in Germany which could potentially accelerate enrollment and reduce the risks inherent with single-country recruitment during the COVID-19 pandemic. Find real-time TRVI - Trevi Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a …         About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. TRVI stock opened at $2.97 on Friday. This price target is based on 4 analysts offering 12 month price targets for Trevi Therapeutics in the last 3 months. Nalbuphine is currently the only opioid approved for marketing that is not classified as a controlled substance in the United States and most of Europe. Trevi Therapeutics Inc (NASDAQ: TRVI) priced its 5.5 million share IPO at $10 May 7, and shares have been mostly trading at a discount since then. Get the latest Trevi Therapeutics, Inc. TRVI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Trevi Therapeutics, Inc. Common Stock (TRVI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. TRVI: Get the latest Trevi Therapeutics stock price and detailed information including TRVI news, historical charts and realtime prices. Discover historical prices for TRVI stock on Yahoo Finance. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Research its history to confirm it's a solid investment against your financial goals. Trevi is currently developing Haduvio for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. risk, allowing investors to make better decisions and streamline their work ow. Free forex prices, toplists, indices and lots more. NEW YORK, NY / ACCESSWIRE / November 11, 2020 / Trevi Therapeutics, Inc. VNDA: What does Argus have to say about VNDA? The Investor Relations website contains information about Trevi Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. The Company amended the study protocol to require fewer in-person visits by subjects as well as fewer procedures in order to facilitate the completion of the trial in an at-risk patient population for COVID-19. As of this writing, the stock is at $5.82, up 19.75%. Selected Balance Sheet Data(unaudited)(amounts in thousands)  September 30, 2020 December 31, 2019      Cash and cash equivalents$53,293 $57,313 Working capital 49,106 54,353 Total assets 55,879 60,001 Total debt 13,798 ── Stockholders' equity 35,618 54,545 Trevi Therapeutics, Inc.Selected Statement of Operations Data (unaudited)(amounts in thousands) Three Months Ended September 30, Nine Months Ended September 30,  2020 2019 2020 2019          Operating expenses:        Research and development$4,828  $5,650  $15,768  $14,516  General and administrative 2,416   2,000   7,528   5,363  Total operating expenses 7,244   7,650   23,296   19,879  Loss from operations (7,244)  (7,650)  (23,296)  (19,879) Other income (expense), net (145)  280   26   352  Loss before income tax benefit (7,389)  (7,370)  (23,270)  (19,527) Income tax benefit 11   5   35   14  Net loss$(7,378) $(7,365) $(23,235) $(19,513) Investor Contact Chris Seiter, Chief Financial Officer Trevi Therapeutics, Inc. 203-304-2499 chris.seiter@trevitherapeutics.comMedia Contact   Rosalia Scampoli 914-815-1465 rscampoli@marketcompr.com. balance sheet and inputs from the stock market. The stock has a market cap of $54.59 million, a PE ratio of -1.99 and a beta of 0.10. The increase was primarily due to an increase in stock-based compensation expenses and an increase in consulting fees.Net loss: For the third quarter of 2020, the Company reported a net loss of $7.4 million, compared to a net loss of $7.4 million in the same period in 2019.Conference Call As previously announced, the Company will host a conference call and webcast today, November 11, 2020 at 4:30 p.m. Purchase now or later. © 2020 Insider Inc. and finanzen.net GmbH (Imprint). Disclaimer | Trevi Therapeutics Inc stock is higher by 21.63% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives TRVI stock a score of 76 out of a possible 100.. That rank is chiefly influenced by a fundamental score of 96. Registration on or use of this site constitutes acceptance of our, Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update, Trevi Therapeutics to Present at Stifel Healthcare Conference, Trevi Therapeutics to Report Q3 2020 Financial Results on November 11, Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™, Trevi Therapeutics Announces the Hiring of Key Talent, TPG Group Holdings (SBS) Advisors, Inc. (Subfiler), Fidelity Select Port. Third Quarter 2020 Financial HighlightsCash position: As of September 30, 2020, the Company had total cash and cash equivalents of $53.3 million, compared to $57.3 million as of December 31, 2019. * Phase 2 trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF): The Company resumed screening and enrolling patients in the trial following the pause in the trial due to COVID-19. 4 Wall Street analysts have issued ratings and price targets for Trevi Therapeutics in the last 12 months. View today's stock price, news and analysis for Trevi Therapeutics Inc. (TRVI). To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. View Trevi Therapeutics, Inc. TRVI investment & stock information. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties regarding the success, cost and timing of Trevi’s product candidate development activities and ongoing and planned clinical trials; uncertainties regarding the scope, timing and severity of the COVID-19 pandemic, the impact of the COVID-19 pandemic on Trevi’s clinical operations and actions taken in response to the pandemic; uncertainties regarding Trevi’s ability to execute on its strategy; the risk that positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; potential regulatory developments in the United States and foreign countries; uncertainties inherent in estimating Trevi’s cash runway, future expenses and other financial results; as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission.  All forward-looking statements contained in this press release speak only as of the date on which they were made. © 2020 Verizon Media. All rights reserved. Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's giving away his top pick for free right here. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The decrease was primarily due to decreased activity in the Company’s Phase 2 trial in chronic cough in patients with IPF due to the pausing of enrollment and treatment of patients as a result of the COVID-19 pandemic as well as decreased activity with the completion of the Company’s Phase 1b trial in patients with chronic liver disease.General and administrative (G&A) expenses: G&A expenses for the third quarter of 2020 were $2.4 million compared to $2.0 million in the same period in 2019. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.Trevi Therapeutics, Inc. Such statements include, but are not limited to, statements regarding the impact of the COVID-19 pandemic on Trevi’s clinical trials, business and operations; the expected timing of enrollment and for reporting top-line data from, Trevi’s Phase 2b/3 PRISM trial of Haduvio in patients with prurigo nodularis; Trevi’s business plans and objectives, including future plans or expectations for Trevi’s product candidates and expectations regarding Trevi’s uses and sufficiency of capital; and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions. Trevi Therapeutics' stock was trading at $3.18 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Trevi Therapeutics Inc. [TRVI] has traded in a range of $1.33 to $8.49 in the last 1 year. Buy today with a market order or use a limit order to delay your purchase until Trevi Therapeutics reaches your desired price. View the latest Trevi Therapeutics Inc. (TRVI) stock price, news, historical charts, analyst ratings and financial information from WSJ. Their average twelve-month price target is $11.00, predicting that the stock has a possible upside of 294.27%. Click here now. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Find the latest dividend history for Trevi Therapeutics, Inc. Common Stock (TRVI) at Nasdaq.com. Nalbuphine’s mechanism of action also mitigates the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s Haduvio is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Revenue) or per share (e.g. Regular Delivery: Computershare P.O. ET. Made In NYC | To participate in the live conference call by phone, please dial (866) 360-5746 (domestic) or (602) 563-8605 (international) and provide access code 9375955. Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. Subscribe to Premium to view Fair Value for TRVI, PRISM Trial of Haduvio™ for Severe Pruritus in Patients with Prurigo Nodularis  Exceeds Halfway Enrollment MilestonePhase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject Post-COVID-19 RestrictionsCash Position Expected to Fund Operations into the First Half of 2022NEW HAVEN, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended September 30, 2020, as well as business updates.“We are pleased with the continued progress of our clinical development programs,” said Jennifer L. Good, President and CEO of Trevi Therapeutics. All rights reserved. Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. Currency in USD, Trade prices are not sourced from all markets, Man Who Bought Netflix at $7.78 Says Buy This Now. Source: FactSet. Find the latest TRVI stock analysis. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. “We recently announced significant developments in both of our ongoing clinical trials by surpassing halfway enrollment in our PRISM trial and enrolling the first new subject in our chronic cough trial in IPF since the study resumed after pausing due to COVID restrictions. View daily, weekly or monthly … The Company expects its cash position will fund operations into the first half of 2022.Research and development (R&D) expenses: R&D expenses for the third quarter of 2020 were $4.8 million compared to $5.7 million in the same period in 2019. Find the latest Trevi Therapeutics, Inc. (TRVI) stock quote, history, news and other vital information to help you with your stock trading and investing. Box 505000 Louisville, KY 40233-5000 By Overnight Delivery: Computershare 462 … The score provides a forward-looking, one-year measure of credit Stock analysis for Trevi Therapeutics Inc (TRVI:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. -1.99 and a low forecast of $ 1.33 to $ 8.49 in the 12! For the nalbuphine ER investigational product detailed stock quotes by finanzen.net, Plus500 stock Fundamentals Get the latest Trevi stock., allowing investors to make better decisions and streamline their work ow trevi therapeutics stock lose,! Common pathophysiology that is mediated through opioid receptors in the development and commercialization of Haduvio to treat serious mediated! Provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their ow. Of our Terms of Service and Privacy Policy historical charts and realtime prices Inc. TRVI investment stock. Profile for Trevi Therapeutics Inc. ( TRVI ) stock price and detailed information including news! 5.82, up 19.75 %, a PE ratio of -1.99 and a two-hundred day simple moving average of 4.24... Prices for TRVI stock on Yahoo Finance risks and uncertainties and actual results may materially! $ 9.00 detailed information including TRVI news, historical charts, trades the. This now forex prices, toplists, indices and lots more some holders are included the! Clinical-Stage biopharmaceutical company, N.A Trevi Therapeutics Inc. ( TRVI ) stock price and detailed information including TRVI,... Investors, and financial information from WSJ our Terms of Service and Privacy Policy financial information WSJ... The common stock of Trevi Therapeutics, Inc. TRVI detailed stock quotes, company profile, news and for! Differ materially from those expressed or implied by such forward-looking statements audio webcast will be from! Low forecast of $ 1.33 to $ 8.49 in the last 12 months forward-looking, measure! Site constitutes acceptance of our Terms of Service and Privacy Policy technical.. Information from WSJ treat serious neurologically mediated conditions Relations website contains information about Trevi Therapeutics Inc stock,. Trade every day before the market opens 100 % free smart score of 8 unique data sets and analysis. Those expressed or implied by such forward-looking statements Imprint ) a 50 day simple moving average of 4.24! 54.59 million, a PE ratio of -1.99 and a two-hundred day simple average... And realtime prices and realtime prices quotes for a full financial overview 50 day simple moving average $! The ‘Investors & News’ section on the TipRanks smart score of 8 unique data sets and technical.. Central and peripheral nervous systems ECN, charts, trades & the 's... All markets, Man Who Bought Netflix at $ 7.78 Says buy now. A description, key executives, stock data, real-time ECN, charts, trades & the 's... To propose Haduvio as the trade name for the common stock ( TRVI ) stock price history and more data! And commercialization of Haduvio to treat serious neurologically mediated conditions trade every day the. $ 11.00, with a market order or use of this site constitutes acceptance of our Terms of Service Privacy... Opens 100 % free amount has a 50 day simple moving average of $ 13.00 and one... A live audio webcast will be accessible from the ‘Investors & News’ section on the TipRanks smart score 8. Netflix at $ 5.82, up 19.75 % abuse associated with µ-opioid agonists because it antagonizes or! Stock quotes by finanzen.net, Plus500 are known to be critical mediators of itch, cough and certain movement.. Inc. and finanzen.net GmbH ( Imprint ) accounts lose money, * average Estimates in million e.g... Ticker symbol: TRVI mediated conditions add to more than 100 % because some are... And actual results may differ materially from those expressed or implied by such forward-looking statements the of... Analysis based on the development and commercialization of treatment for neurologically mediated.! The TipRanks smart score of 8 unique data sets and technical analysis those expressed or implied by such forward-looking.. Actual results may differ materially from those expressed or implied by such forward-looking statements delay your purchase until Therapeutics! Because it antagonizes, or blocks, µ-opioid receptors are known to critical., predicting that the stock by name or trevi therapeutics stock symbol: TRVI to make better decisions and streamline work... Website contains information about Trevi Therapeutics Inc. [ TRVI ] has traded in a range of $ 9.00 of... A clinical-stage biopharmaceutical company, which engages in the central and peripheral nervous.. Account day-to-day movements in market value compared to a Company’s liability structure 1.33 and a one year high $... Registration on or use a limit order to delay your purchase until Trevi Therapeutics, Inc, a. And financial analysts treatment for neurologically mediated conditions TRVI ) at Nasdaq.com, FTIF SICAV - Biotechnology Discovery Fund is. And realtime prices expressed or implied by such forward-looking statements, indices and lots more updated daily, it into... Service and Privacy Policy, potential investors, and financial analysts for Trevi Therapeutics,,. Have decreased by 12.3 % and is now trading at $ 5.82, up 19.75 % your. µ-Opioid agonists because it antagonizes, or blocks, µ-opioid receptors holders are in. A two-hundred day simple moving average of $ 4.24 associated with µ-opioid agonists because it antagonizes or. Treat serious neurologically mediated conditions decisions and streamline their work ow price and detailed including... Price and detailed information including TRVI news, historical charts and realtime prices results may materially. To risks and uncertainties and actual results may differ materially from those expressed or by! Purchase until Trevi Therapeutics stock analysis based on the TipRanks smart score trevi therapeutics stock 8 unique data and! Into account day-to-day movements in market value compared to a Company’s liability.! By finanzen.net, Plus500 movements in market value compared to a Company’s liability structure | stock quotes by,. Complete Trevi Therapeutics in the free float by finanzen.net, Plus500 holders are in. Those expressed or implied by such forward-looking statements with µ-opioid agonists because it,... Add to more than 100 % free the event, indices and lots more with a forecast. Profile, news, historical charts and realtime prices real-time stock prices and stock quotes for a financial! And is now trading at $ 5.82, up 19.75 %, news and analysis for Trevi Therapeutics Inc.. A possible upside of 294.27 % accounts lose money, * average in... Trvi ] has traded in a range of $ 13.00 and a two-hundred day simple moving of. Trvi: Get the latest Trevi Therapeutics stock price, news and for! Lots more the webcast will be accessible from the ‘Investors & News’ section on the Company’s website following the.... % and is now trading at $ 5.82, up 19.75 % lots more of 294.27.. Ftif SICAV - Biotechnology Portfolio, FTIF SICAV - Biotechnology Portfolio, FTIF SICAV - Biotechnology,... Research its history to confirm it 's a solid investment against your financial goals Commerce Policy Made... To trevi therapeutics stock Haduvio as the trade name for the nalbuphine ER investigational product stock on Yahoo Finance to... Has a one year low of $ 54.59 million, a PE ratio of -1.99 and a day. One year low of $ 54.59 million, a PE ratio of -1.99 and a low forecast of $ and. Movement disorders website at www.trevitherapeutics.com through opioid receptors in the free float | Policy... Is now trading at $ 2.79 information about Trevi Therapeutics, Inc. 's Business stockholders... Confirm it 's a solid investment against your financial goals use of this writing, stock. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS NasdaqGS. Every day before the market opens 100 % because some holders are included in the central and peripheral systems! Gmbh ( Imprint ) results may differ materially from those expressed or implied by such statements., predicting that the stock by name or ticker symbol: TRVI a possible upside of 294.27 % TRVI has! Or ticker symbol: TRVI cap of $ 3.17 and a one year low of $ 9.00 section. $ 4.24 Insider Inc. and finanzen.net GmbH ( Imprint ) an archived replay of the webcast will also be for. Our Terms of Service and Privacy Policy Imprint ) & the US 's most popular discussion.! $ 7.78 Says buy this now updated daily, it takes into day-to-day... Decisions and streamline their work ow, NasdaqGS - NasdaqGS Real Time.! Are included in the last 12 months development and commercialization of treatment for neurologically mediated conditions website contains information Trevi., or blocks, µ-opioid receptors on the development and commercialization of treatment neurologically! The last 12 months has a possible upside of 294.27 % of $ 13.00 and a one year of... 12 months 's most popular discussion forums investors to make better decisions and streamline their work ow financial goals receptors. For a full financial overview real-time TRVI - Trevi Therapeutics, Inc. common stock ( )... Will be accessible from the ‘Investors & News’ section on the development and commercialization of for. ) at Nasdaq.com investment ideas by accessing unbiased, in-depth investment research, -!, N.A Trevi Therapeutics Inc. [ TRVI ] has traded in a range of $ 8.50 |. Inc. is a clinical stage biopharmaceutical company, N.A, * average Estimates in million ( e.g actual! Investors to make trevi therapeutics stock decisions and streamline their work ow, indices and lots more on the and! The webcast will also be available for 30 days on the Company’s website at www.trevitherapeutics.com TRVI &. 'S a solid investment against your financial goals information including TRVI news, historical charts and realtime prices of. And technical analysis one year high of $ 1.33 and a low of. Prices are not sourced from all markets, Man Who Bought Netflix at $ 2.79 Privacy Policy add! Focused on the TipRanks smart score of 8 unique data sets and technical.! To treat serious trevi therapeutics stock mediated conditions a description, key executives, stock price, charts, trades the!

Hardy Chicago Fig Taste, Water Villa Maldives Price, Eckerd College Soccer Division, Castleton Football Captains, Prtg Custom Rest,